by admin_63069 | Dec 18, 2024 | Related Topics
Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed.
by admin_63069 | Dec 11, 2024 | Related Topics
Focal therapy adoption is increasing, transitioning from skepticism to optimism, with more practitioners offering these treatments.
by admin_63069 | Dec 4, 2024 | Related Topics
Johns Hopkins Medicine-led research is believed to be the first to provide evidence of this association.
by admin_63069 | Nov 27, 2024 | Related Topics
Among patients with hormone-sensitive prostate cancer, circulating tumor cell (CTC) count at the start of treatment may be able to indicate which patients are likely to live longer after treatment, as well as those who may be good candidates for novel therapies and...
by admin_63069 | Nov 20, 2024 | Related Topics
Efficacy, trials, and combination therapies
by admin_63069 | Nov 14, 2024 | Related Topics
Researchers say inadequate understanding of risks may lead patients to regret treatment decisions.
